Scarica l'app Stockscreener
1.975
1.49%
-0.035
Precedente Chiudi:
$2.01
Aprire:
$2.02
Volume 24 ore:
205.94K
Relative Volume:
0.23
Capitalizzazione di mercato:
$279.63M
Reddito:
$893.00K
Utile/perdita netta:
$-151.61M
Rapporto P/E:
-3.8335
EPS:
-0.5152
Flusso di cassa netto:
$-135.31M
1 W Prestazione:
+4.21%
1M Prestazione:
-7.91%
6M Prestazione:
-34.87%
1 anno Prestazione:
+148.77%
Intervallo 1D:
$1.96
$2.03
Intervallo di 1 settimana:
$1.84
$2.035
Portata 52W:
$0.54
$7.13
Prokidney Corp Stock (PROK) Company Profile
Nome
Prokidney Corp
Settore
Industria
Telefono
336-999-7028
Indirizzo
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.97 | 285.31M | 893.00K | -151.61M | -135.31M | -0.5152 |
VRTX
Vertex Pharmaceuticals Inc
|
440.40 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.50 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
831.13 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
326.54 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.35 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2025-06-30 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Iniziato | JP Morgan | Neutral |
| 2024-09-10 | Iniziato | Guggenheim | Buy |
| 2024-03-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-07-25 | Iniziato | BTIG Research | Buy |
| 2022-12-21 | Iniziato | Jefferies | Buy |
| 2022-11-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Iniziato | UBS | Buy |
| 2022-10-14 | Iniziato | Citigroup | Buy |
| 2022-09-23 | Iniziato | BofA Securities | Buy |
| 2022-09-02 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Prokidney Corp Borsa (PROK) Ultime notizie
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ProKidney (NASDAQ:PROK) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Bull Run: Can ProKidney Corp continue delivering strong returns2026 Key Highlights & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Winners Losers: Is ProKidney Corp impacted by rising rates2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
High stakes: ProKidney pushes toward commercialization as cash dwindles, opportunity awaits - The Business Journals
Analysis Recap: Will ProKidney Corp benefit from government policyQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
April 2026 Penny Stock Highlights - Sahm
Hennion & Walsh Asset Management Inc. Has $3.37 Million Holdings in ProKidney Corp. $PROK - MarketBeat
Analysis Recap: What is the long term forecast for ProKidney Corp stockTrade Performance Summary & Low Drawdown Trading Strategies - baoquankhu1.vn
What Makes ProKidney Corp. (PROK) So Attractive - Yahoo Finance
Sell Signal: Will ProKidney Corp benefit from geopolitical trendsTrade Risk Summary & Real-Time Market Trend Scan - baoquankhu1.vn
Revenue Check: Does ProKidney Corp outperform in volatile markets2026 Drop Watch & Consistent Profit Trading Strategies - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Shares Up 5.9%Here's Why - MarketBeat
5 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Investment Report: What are the future prospects of ProKidney Corp2026 Earnings Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
ProKidney (MEX:PROK) PB Ratio : (As of Mar. 27, 2026) - GuruFocus
ProKidney hires chief commercial officer as key clinical test results near - Winston-Salem Journal
ProKidney names Greg Madison as chief commercial officer By Investing.com - Investing.com Australia
ProKidney appoints Greg Madison as chief commercial officer - TipRanks
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer - Bitget
ProKidney names Greg Madison as chief commercial officer - Investing.com
ProKidney expands senior leadership team with appointment of Greg Madison as chief commercial officer - marketscreener.com
Prokidney Expands Senior Leadership Team With Appointment Of Greg Madison As Chief Commercial Officer - TradingView
ProKidney (NASDAQ:PROK) Trading Down 7.6%Here's What Happened - MarketBeat
Q2 Earnings Forecast for ProKidney Issued By HC Wainwright - MarketBeat
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insider Sell: Does ProKidney Corp offer margin of safety2026 Outlook & Capital Efficiency Focused Ideas - baoquankhu1.vn
ProKidney A: Fundamental Analysis and Financial Ratings | PROK | KYG7S53R1049 - marketscreener.com
ProKidney (NASDAQ:PROK) Cut to Sell at Wall Street Zen - MarketBeat
ProKidney narrows loss to $150M as it eyes crucial kidney treatment trial results - The Business Journals
Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Equities Analysts Set Expectations for ProKidney Q1 Earnings - MarketBeat
Guggenheim Sticks to Its Buy Rating for ProKidney (PROK) - The Globe and Mail
ProKidney’s Greensboro Facility Could Shield It From Looming Tariff Risks—But Time Is Short - Bitget
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability - TipRanks
ProKidney Makes Major Wager on U.S. Tariff Relief—Does Consistent Policy Support a $485M Risk? - Bitget
ProKidney ends fiscal 2025 with bigger loss, larger revenue stream - Winston-Salem Journal
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating - TipRanks
ProKidney (NASDAQ:PROK) Raised to "Strong-Buy" at Jefferies Financial Group - MarketBeat
ProKidney Corp. 2026 10-K Report: Business Overview, Clinical Trials, Risks, and Financial Highlights - Minichart
BofA reiterates ProKidney stock Underperform rating at $1 target By Investing.com - Investing.com South Africa
ProKidney Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BofA reiterates ProKidney stock Underperform rating at $1 target - Investing.com
ProKidney (NASDAQ:PROK) Releases Earnings Results - MarketBeat
ProKidney Reports Full Year 2025 Financial Results and Business Highlights - Bitget
PROK: FDA alignment, strong clinical progress, and cash runway into 2027 despite ongoing losses - TradingView
ProKidney (Nasdaq: PROK) details 2025 loss and cash runway into 2027 - Stock Titan
ProKidney (PROK) advances Phase 3 rilparencel program for diabetic CKD - Stock Titan
ProKidney’s High Cash Usage Dims Pipeline Hopes—Investors Brace for Funding Shortfall Before 2027 Results - bitget.com
ETF Watch: How volatile is ProKidney Corp stock2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Aug Update: Why is ProKidney Corp stock going downRisk Management & AI Powered Market Entry Ideas - baoquankhu1.vn
Prokidney Corp Azioni (PROK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
1.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):